Frevert, M. L. http://orcid.org/0000-0002-6497-7051
Dannehl, D.
Jansen, L.
Hermann, S.
Schäffler, H.
Huwer, S.
Janni, W.
Juhasz-Böss, I.
Hartkopf, A. D.
Taran, F.-A.
Funding for this research was provided by:
Universitätsklinikum Freiburg
Article History
Received: 17 December 2023
Accepted: 28 January 2024
First Online: 12 March 2024
Declarations
:
: Marie Louise Frevert- speaker honoraria from Novartis; Dominik Dannehl–travel support by Daiichi Sankyo and Gilead and honoraria by Gilead; Lina Jansen- none; Silke Hermann- none; Henning Schäffler–honoraria by Novartis; Sarah Huwer- none; Wolfgang Janni: research grants and/or honoraria from AstraZeneca, Cellgene, Chugai, DaiichiSankyo, Eisai, ExactScience, GSK, Janssen, Lilly, Menarini, MSD, Novartis, Sanofi-Aventis, Roche, Pfizer, Seagen; Ingolf Juhasz-Böss- none; Andreas D. Hartkopf–honoraria and travel support by AstraZeneca, Agendia, Amgen, Clovis, Daiichi Sankyo, Eisai, ExactSciences, Gilead, GSK, MSD, Novartis, Pfizer and Roche; Florin-Andrei Taran- received speaker and consultancy honoraria from Astra Zeneca, ExactSciences, Gilead, GSK, Hexal, MSD, Novartis, Onkowissen, Pfizer, Roche, Tesaro.